LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals
Theranostics · 02.01.2025 · 15 (5) · 1864-1878
DOI: 10.7150/thno.99490 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Theranostics, erschienen am 02.01.2025. Verfasst von Arifudin Achmad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine and Molecular Theranostics, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, West Java, Indonesia. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Positron-Emission Tomography, Neoplasms, Large Neutral Amino Acid-Transporter 1. Die Arbeit wurde bisher 15-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The quest for a cancer-specific positron emission tomography (PET) tracer has been ongoing for decades.Current evidence shows that targeting amino acid metabolism dysregulation is a valid alternative cancer detection method and can complement the conventional approach, which relies on targeting increased glucose metabolism.The rate of amino acid metabolism in all major organs is mostly equally low and does not change in any physiological dynamics.The amino acid metabolism rate only spikes in malignant tissues.PET imaging targeting LAT1 (L-type amino acid transporter 1) demonstrated accurate cancer imaging of various cancer types with nearly negligible background uptake.LAT1 is a pan-cancer biomarker of amino acid metabolism dysregulation.The upregulated LAT1 expression in cancer cells depicts their dynamic behavior and aggressiveness.This review discussed PET radiotracers developed as a LAT1-specific agent and how this new class of cancer-specific radiopharmaceuticals could deliver PET images with clinical properties we yearn for, such as high specificity toward various malignancies, robust non-cancer exclusion (mainly inflammatory reactions), accurate malignant lesion delineation, representative therapeutic monitoring, and long-term prognostication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine and Molecular Theranostics, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, West Java, Indonesia.
- Theranostic Radiopharmaceutical Research Collaboration Center, Universitas Padjadjaran, Sumedang 45363, West Java, Indonesia.
- Oncology and Stem Cell Study Center, Faculty of Medicine, Universitas Padjadjaran, Bandung 40161, West Java, Indonesia.
- Faculty of Medicine, Kansai Medical University, Hirakata 573-1010, Japan.
- Department of Radiotheranostics, Gunma University Graduate School of Medicine, Maebashi 3718511, Japan.
- Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, West Java, Indonesia.
Zitieren
APA
Achmad, A., Hanaoka, H., Holik, H. A., Endo, K., Tsushima, Y., & Kartamihardja, A. H. S. (2025). LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals. Theranostics, 15(5), 1864-1878. https://doi.org/10.7150/thno.99490
Vancouver
Achmad A, Hanaoka H, Holik HA, Endo K, Tsushima Y, Kartamihardja AHS. LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals. Theranostics. 2025;15(5):1864-1878. doi:10.7150/thno.99490
BibTeX
@article{Achmad2025,
author = {Achmad, Arifudin and Hanaoka, Hirofumi and Holik, Holis Abdul and Endo, Keigo and Tsushima, Yoshito and Kartamihardja, Achmad Hussein S},
title = {LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals},
journal = {Theranostics},
year = {2025},
volume = {15},
number = {5},
pages = {1864--1878},
doi = {10.7150/thno.99490}
}
EUVIMED